Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568826 | 0.86 | TLR4 (0.42) | TLR4TLR2PARP10PARP15HPGD | |
| SCHEMBL16900519 | 0.86 | TLR4 (0.43) | TLR4TLR2PARP10PARP15HPGD | |
| SCHEMBL2207765 | 0.85 | TLR4 (0.43) | TLR4TLR2PARP10PARP15 | |
| SCHEMBL2207743 | 0.85 | TLR4 (0.43) | TLR4TLR2PARP10PARP15 | |
| SCHEMBL27197634 | 0.83 | TLR4 (0.45) | TLR4TLR2PARP10PARP15HPGD | |
| SCHEMBL2208003 | 0.75 | PARP10 (0.45) | PARP10PARP15 | |
| SCHEMBL2208152 | 0.75 | PARP10 (0.39) | TLR4TLR2PARP10PARP15KAT6A | |
| SCHEMBL2208146 | 0.75 | PARP10 (0.39) | TLR4TLR2PARP10PARP15KAT6A | |
| SCHEMBL12077349 | 0.73 | KAT6A (0.46) | PARP10PARP15KAT6A | |
| SCHEMBL4568835 | 0.71 | CHRNB2 (0.41) | PARP10PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079825-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885PARP10 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.